

## Hematologic Dysfunction Criteria in Critically Ill Children:

### The PODIUM Consensus Conference


Jennifer A Muszynski, MD, MPH<sup>a</sup>; Jill M Cholette, MD<sup>b</sup>; Marie E Steiner, MD, MS<sup>c</sup>; Marisa Tucci, MD<sup>d</sup>; Allan Doctor, MD<sup>e</sup>; Robert I Parker, MD<sup>f</sup>, on behalf of the PODIUM Collaborative

### Data Supplement

#### Table of Contents

| Content  | Pages |
|--|-------|
| <b>Supplemental Figure 1.</b> Risk of Bias Assessment Summary for Studies Included in the PODIUM Hematologic Dysfunction Systematic Review (n=29 studies)      | 2     |
| <b>Supplemental Table 1.</b> Studies Included in the PODIUM Hematologic Dysfunction Systematic Review (n=29 studies)   | 3-5   |
| <b>Supplemental Table 2.</b> Performance Characteristics for Assessment Tools and Scores for Hematologic Dysfunction in Critically Ill Children (n=29 studies) | 6-9   |
| <b>References</b>  | 10-11 |
| <b>Research Priorities</b>   | 12    |

**Supplemental Figure 1.** Risk of Bias Assessment Summary for Studies Included in the PODIUM Hematologic Dysfunction Systematic Review (n=29 studies)



**Supplemental Table 1. Studies Included in the PODIUM Hematologic Dysfunction Systematic Review (n=29 studies)**

| Author (yr)             | Funding                                     | Study design                      | Location                            | No. of sites | Study start year | Study end year | Setting  | Data source(s)              | Sample size                                      | Recruitment            | Age categories <sup>a</sup>  | Age details <sup>b</sup>  |
|-------------------------|---|-----------------------------------|-------------------------------------|--------------|------------------|----------------|--|-----------------------------|--|------------------------|------------------------------|---|
| An 2016                 | Govt.                                       | Retrospective cohort              | China                               | 1            | 2000             | 2012           | PICU of unknown composition                                | Chart review                | 29   | Consecutive            | Infants                      | Median 6 yr [range 0.5-16]  |
| Bestati 2010            | Govt.                                       | Prospective cohort                | France, Canada, Switzerland         | 7            | 1998             | 2000           | PICU of unknown composition                                | Prospective data collection | 1806   | Consecutive            | Children                     | 525 infants aged 1 mo to < 1 yr; 853 children aged 1 yr to < 12 yr; 257 adolescents aged 12 yr to < 18 yr |
| Castellanos-Ortega 2002 | NR  | Retrospective cohort              | Spain                               | 14           | 1983             | 1995           | PICU of unknown composition                                | Chart review                | 350  | Consecutive            | Adolescents                  | Mean 30.9 (2.27) (derivation cohort) 33.3 (3.04) (validation cohort)                                      |
| Chhangani 2015          | NR  | Prospective cohort                | India                               | 1            | 2012             | 2013           | PICU of unknown composition                                | Prospective data collection | 100  | Consecutive            | Neonates                     | Mean 4.97 (3.31) yr (survivors); 4.92 (3.87) yr (non-survivors)   |
| Choi 2017               | NR  | Retrospective cohort              | Korea                               | 1            | 2012             | 2015           | PICU of unknown composition                                | Chart review                | 83   | Consecutive            | Infants                      | Mean 128 (159.6) mo   |
| Couto-Alves 2013        | Govt.                                       | Retrospective cohort              | United Kingdom, Austria and Holland | 6            | 1996             | 2011           | PICU of unknown composition                                | Prospective data collection | 309 development, 623 validation, 134 replication | NR/Unable to determine | Children                     | Mean 5.12 (0.3) yr  |
| da Silva 2008           | NR  | Retrospective cohort              | Brazil                              | 1            | 1998             | 2001           | Other Oncologic PICU                                       | Chart review                | 196  | Consecutive            | Infants                      | Mean 8.4 (5.4) yr   |
| Fijnvandraat 1995       | NR  | Case series                       | The Netherlands                     | 1            | 1990             | 1992           | PICU of unknown composition                                | Prospective data collection | 35   | Consecutive            | Children                     | Median 4.3 [0.13-15] yr   |
| Gonzalez-Vicent 2005    | Other: Fundacion Oncohematologia Pediatrica | Retrospective cohort              | Spain                               | 1            | 1998             | 2002           | PICU of unknown composition Hospital floor outside the ICU | Chart review                | 198  | Consecutive            | Adolescents                  | Median 7 [1-18] yr  |
| Hu 2017                 | Govt.                                       | Case/control study                | China                               | 1            | 2010             | 2016           | Emergency room   | NR/Unable to determine      | 296 for derivation and 68 for validation         | Consecutive            | Children                     | Mean 7.8 (3.13) yr in non-PHI group and 8.19 (3.28) yr in PHI group                                       |
| Jhang 2016              | NR  | Other retrospective observational | Korea                               | 1            | 2013             | 2014           | Mixed PICU   | Chart review                | 191  | Consecutive            | Infants Children Adolescents | Mean 29 mo [2-215]  |

|                   |       |                      |                |   |      |      |                             |   |   |                        |  |  |
|-------------------|-------|----------------------|----------------|---|------|------|-----------------------------|---|---|------------------------|--|--|
| Kornelisse 1997   | NR    | Prospective cohort   | Netherlands    | 1 | 1988 | 1995 | PICU of unknown composition | Chart review<br>Prospective data collection | 75  | Consecutive            | NR/Unable to determine                   | Median 3.2 y (3 weeks-17.9 y)  |
| Leteurtre 2001    | NR    | Prospective cohort   | France         | 1 | 1993 | 2000 | PICU of unknown composition | Prospective data collection                 | 58  | Consecutive            | Neonates                                 | Median 24 mo [IQR 12-44 mo]  |
| Malley 1996       | NR    | Retrospective cohort | USA            | 3 | 1985 | 1994 | NR/Unable to determine      | Chart review                                | 245   | Other                  | Infants                                  | Median 24 mo [0.7-228 mo]  |
| Martins 2015      | NR    | Retrospective cohort | Portugal       | 1 | 2000 | 2013 | NR/Unable to determine      | Chart review<br>Other unit database         | 76  | Consecutive            | Children                                 | 'all children'   |
| Meyer 2005        | NR    | Retrospective cohort | Germany        | 1 | 2001 | 2003 | PICU of unknown composition | Chart review                                | 32  | Consecutive            | Children                                 | Median 11.5 y, range 1 mo-22 y   |
| Peters 2001       | NR    | Prospective cohort   | United Kingdom | 3 | 1993 | 1999 | PICU (non-cardiac only)     | Chart review<br>Prospective data collection | 32 in derivation set; 195 in validation set | Consecutive            | Infants, Children                        | Survivors (n = 26): Median 2y [IQR: 1y – 5y]<br>NS (n=6): Median 0 y [IQR: 0y – 2.5y]                          |
| Silva 2007        | NR    | Retrospective cohort | Brazil         | 2 | 2000 | 2005 | PICU of unknown composition | Chart review                                | 72  | NR/Unable to determine | Infants, children                        | Range 2 - 156 mo<br>Survivors (n = 54): Median 33 [IQR: 14 – 60] mo<br>NS (n = 14): Median 28 [IQR: 9 – 48] mo |
| Ramby 2015        | Govt. | Retrospective cohort | USA            | 1 | 2009 | 2010 | PICU of unknown composition | Chart review                                | 596   | Consecutive            | Not reported                             | Median 4.4 [IQR: 1.5 – 12.9] yr  |
| Li 2019           | none  | Prospective cohort   | China          | 1 | 2015 | 2018 | PICU of unknown composition | Chart review<br>Prospective data collection | 404   | NR/unable to determine | Children, adolescents                    | Median 12 mo [IQR: 4 – 60 mo]  |
| Said 2017         | Govt. | Retrospective cohort | USA            | 1 | 2005 | 2012 | Mixed PICU                  | Chart review                                | 3913  | Consecutive            | Not reported                             | Mean 7.45 (6.7) yr   |
| Kim 2019          | Govt. | Retrospective cohort | Korea          | 1 | 2009 | 2017 | PICU of unknown composition | Chart review                                | 101   | Consecutive            | Unable to determine                      | Median 13 [IQR: 8 – 16] yr   |
| Niederwanger 2018 | none  | Retrospective cohort | Austria        | 1 | 2000 | 2014 | PICU of unknown composition | Chart review                                | 250   | Consecutive            | Neonates, Infants, Children, Adolescents | Median 35 [IQR: 6 – 109] mo  |

|               |              |                      |       |   |      |      |                             |              |      |             |                                |  |
|---------------|--------------|----------------------|-------|---|------|------|-----------------------------|--------------|------|-------------|--------------------------------|--|
| Ye 2018       | Govt.        | Retrospective cohort | China | 1 | 2014 | 2016 | PICU of unknown composition | Chart review | 4723 | Consecutive | Infants, Children, Adolescents | Mean 3.3 (3.8) yr  |
| Nam 2018      | Govt.        | Retrospective cohort | Korea | 1 | 2016 | 2016 | PICU of unknown composition | Chart review | 232  | Consecutive | Not reported                   | Mean 7.2 (5.9) yr (control, N=201); mean 7.9 (7.1) yr (SIRS, N=25); mean 10.8 (5.6) yr (sepsis, N=6) |
| Jain 2018     | Not reported | Prospective cohort   | India | 1 | 2014 | 2015 | PICU of unknown composition | Chart review | 141  | Consecutive | Children                       | Mean 19.5 (18.3) mo  |
| Kalkwarf 2018 | Not reported | Retrospective cohort | USA   | 1 | 2010 | 2016 | Trauma center               | Chart review | 1292 | Consecutive | Infants, Children, Adolescents | Median 14 [IQR: 6-16] yr (survivors, N=1169); Median 11 [IQR: 4-16] yr (NS, N = 123)                 |
| Sachdev 2018  | None         | Retrospective cohort | India | 1 |      |      | PICU of unknown composition | Chart review | 101  | Consecutive | Infants, Children, Adolescents | Median (range): 72 (4-196) mo (NS, N=11); Median (range) 36 (1.5 – 196) mo (Survivors, n = 90)       |
| Purbiya 2018  | None         | Retrospective cohort | India | 1 | 2014 | 2015 | PICU of unknown composition | Chart review | 209  | Consecutive | Children                       | NR   |

Abbreviations: Govt., government; NGO, nongovernmental organization; NR, NR; PICU, pediatric intensive care unit; PCICU, pediatric cardiac intensive care unit; IQR, interquartile range; SD, standard deviation; wks, weeks; mo, months; yr, years

<sup>a</sup> Neonates (0 to 30 days), Infants (31 days to < 1 year), Children (1 year to < 12 years), Adolescents (12 years to < 18 years)

**Supplemental Table 2. Performance Characteristics for Assessment Tools and Scores for Hematologic Dysfunction in Critically Ill Children (n=29 studies)**

| Source Year             | Score/ assessment tool   | Inclusion criteria                                      | Timing of score/tool assessment           | Outcomes  | Performance characteristics  |
|-------------------------|--|---|---|-----------|--|
| An 2016                 | Pediatric Critical Illness Score                                 | HSCT patients   | pre-HSCT and day 1 of PICU                | Mortality | Reports p value for multivariable analysis of 0.04 for pediatric critical illness score. Unadjusted OR 4.2 (1.3, 13.79) for every 10-point decrease in PCIS below a PCIS of 90   |
| Bestati 2010            | Blood cell counts<br>PELOD score                                 | Unable to determine PICU characteristics                | first 7 days of PICU                      | Mortality | AUROC: day 1 PELOD AUROC for mortality 0.78 in neonates; day 1 PELOD AUROC for mortality 0.93<br>Other: OR for hematological portion of PELOD (mortality) for neonates 1.6 (0.96, 2.69); OR for mortality for hematologic portion of PELOD for older children 1.16 (1.09, 1.312)   |
| Castellanos-Ortega 2002 | Blood cell counts<br>Meningococcal septic shock prognostic score | PICU patients with meningococcal septic shock           |   | Mortality | AUROC: AUROC for meningococcal score: 0.91 (derivation cohort) 0.88 (validation cohort)<br>aOR: for leukocyte count less than 4,000 1.55 (95% CI 1.1, 2.2)<br>Goodness of fit: Hosmer Lemeshow p value for meningococcal score: 0.55 (derivation cohort) 0.47 (validation cohort)  |
| Chhangani 2015          | APACHE II score  | Unable to determine PICU characteristics                | PICU day 1                                | Mortality | APACHE II: AUROC: 0.889 (0.85, 0.93)<br>Goodness of fit: Hosmer-Lemeshow p = 0.726<br>Other: WBC 15869.98 +/- 7537 survivors vs. 20307.18 +/- 9036.4 nonsurvivors on univariate analysis, p=0.009<br>Hematocrit not significantly different between survivors and nonsurvivors   |
| Choi 2017               | Blood cell counts  | General PICU population (mixed cardiac and non-cardiac) | within 1 hour of PICU admission           | Mortality | Se: 71.4 (platelet count < 52,000, all patients); 78.6 (platelet count < 30.5, patients with hematologic oncologic diagnosis); 85.7 (platelet count < 106.5, patients without hematologic oncologic diagnosis)<br>Sp: 71 (platelet count < 52,000); 66.7 (platelets < 30.5, patients with hematologic oncologic diagnosis); 78.9 (platelets < 106.5, patients without hematologic oncologic diagnosis)<br>PPV: 45.5 (platelets < 52,000, all patients); 57.9 (platelets < 30.5, patients with hematologic oncologic dx); 42.9 (platelets < 106.5, patients without hematologic oncologic diagnosis)<br>NPV: 88 (platelets < 52, all patients); 84.2 (platelets < 30.5, patients with hematologic oncologic diagnosis); 96.8 (platelets < 106.5, patients without hematologic oncologic diagnosis)<br>LR: 6.11 (all pts); 7.33 (pts with hematologic oncologic diagnosis); 22.5 (pts without hematologic oncologic diagnosis)<br>AUROC: platelet count to predict mortality: 0.8 (95% CI 0.69, 0.9) for all subjects; 0.722 (0.55, 0.9) for patients without hematologic oncologic diagnosis; 0.86 (0.7, 1) for patients with hematologic oncologic diagnosis (n = 38)<br>aOR: 0.988 (95% CI: 0.977, 0.999) |
| Couto-Alves 2013        | Blood cell counts<br>Other<br>INR, aPTT, fibrinogen, platelet    | General PICU population (mixed cardiac and non-cardiac) | lab data from 'the first recorded sample' | Mortality | BEP score (Model constructed by platelet count and base excess) to predict mortality: AUROC: 0.86 (95%CI: 0.8, 0.91)   |
| da Silva 2008           | Blood cell counts<br>Other                                       | Oncology patients                                       | Initial values                            | Mortality | Adjusted HR for initial granulocyte count 1.3 (0.7, 2.7); aHR for duration of granulocytopenia: 2.4 (1.2, 4.9)   |

|                      |   |   |   |   |  |
|----------------------|---|---|---|---|--|
|                      | initial granulocyte count and duration of granulocytopenia          |   |   |   | Variables included in multivariable model to predict mortality:<br>Number of organ dysfunctions (aHR 7.4, p<0.0001), respiratory infection (aHR 2.3; p=0.005), duration of granulocytopenia (aHR 2.4, p=0.02), Initial granulocyte count (aHR 1.3, p=0.4), Underlying disease (aHR 0.8, p=0.4).<br>chi square statistic for model: 51.122, p <0.0001   |
| Fijnvandraat 1995    | Blood cell counts<br>Other coagulation tests and GMPS score         | General PICU population (only non-cardiac)  | within 2 hours of PICU admission              | Mortality   | Mean (SD) platelet count 128 (73) in survivors vs. 65 (61) x 10 <sup>9</sup> /l in non-survivors   |
| Gonzalez-Vicent 2005 | Other 'score of PICU admission'                                     | HSCT patients   | During HSCT procedure                         | Mortality<br>Other PICU admission                           | Kaplan-Meier (for probability of ICU admission) high risk: 63.8 +/- 8.8 v. low risk: 8.8 +/- 2.2%; log rank p < 0.0001<br>Autologous transplant, lower O-PRISM score, lower CRP, lack of multiorgan failure, lack of inotropic drug associated with higher event-free survival on univariate analyses.   |
| Hu 2017              | Blood cell counts<br>Coagulation assays                             | Other ED patients with TBI  | On arrival to ED & initial head CT on arrival | progressive hemorrhagic intracranial hemorrhage             | C-statistic 0.873 (p=0.586) for derivation and Hosmer-Lemeshow tests 0.877 (p=0.524) for validation<br><br>Model to predict progressive hemorrhagic brain injury includes: GCS score, intra-axial bleeding/brain contusion, midline shift, platelet count < 100,000 (aOR 7.86 [2.3, 26.4]), PATIENTS> 14s (aOR 3.1[1.6, 6.2]), INR > 1.25 (aOR 3.92 [1.8, 8.8]), D-dimer >=5 (aOR 9.9 [3.1, 32.2]), hyperglycemia  |
| Jhang 2016           | Blood cell counts<br>ISTH and JAAM DIC scores                       | General PICU population (mixed cardiac and non-cardiac)<br>Oncology patients<br>HSCT patients | Day 1 of PICU admission                       | Mortality   | AUROC: 0.788 for JAAM DIC score and 0.72 for ISTH DIC score<br>JAAM DIC score:<br>>= 3 SIRS criteria (1 point)<br>Platelet count 80 – 120 or 30% decrease within 24 hr (1 point) or < 80 or 50% decrease within 24 hrs (3 points)<br>Prothrombin time (patient / normal value) < 1.2 (1 points) or >= 1.2 (3 points)<br>Fibrinogen degradation product (mg/dL) 10 – 25 (1 point) or >=25 (3 points)<br><br>ISTH DIC score:<br>Platelet count 50- 100 (1 point) or < 50 (2 points)<br>D-dimer 1-5 micrograms/mL (2 points) or > 5 (3 points)<br>Fibrinogen <= 100 dg/L (1 points)<br>Prothrombin time (s) 3 - 6 (1 point) or > 6 (2 points) |
| Kornelisse 1997      | Blood cell counts<br>Rotterdam score                                | General PICU population (mixed cardiac and non-cardiac)                                       | Day 1   | Mortality, amputation, skin grafting, neurologic            | PPV: 86% for Rotterdam score<br><br>Score includes: CRP, serum potassium, base excess, and platelet count)   |
| Leteurtre 2001       | Blood cell counts   | Septic shock with purpura (SSP)   | Day 1   | Mortality   | AUROC: PRISM best at 0.95; other scores also reported  |
| Malley 1996          | Blood cell counts<br>Other perfusion Model 1/<br>fibrinogen Model 2 | Invasive meningococcal disease  | First values obtained                         | death, amputation, or loss of all 5 digits on one extremity | Se: 82% model 1, 89% model 2<br>Sp: 97% model 1, 97% model 2<br>PPV: 87% model 1, 89% model 2<br>NPV: 97% model 1, 97% model 2<br>AUROC: no values given<br>Model 1: ANC < 3,000, poor perfusion, Platelet count < 150<br>Model 2: Fibrinogen < 250, ANC < 3,000   |

|                 |   |   |   |  |  |
|-----------------|---|---|---|--|--|
| Martins<br>2015 | Blood cell counts<br>Base excess (BEP score)<br>Base excess x platelet<br>count | Invasive<br>meningococcal<br>disease                              | Day 1   | Mortality,<br>Categories of<br>organ<br>dysfunction in<br>survivors vs.<br>non-survivors | Base excess and platelet count score (BEP score)<br>AUROC: 0.81 (95% CI: 0.66 – 0.97)<br>For cutoff of 0.06:<br>Se: 83<br>Sp: 83<br>PRISM: AUROC 0.96 (0.91 - 1)<br>Hematological organ failure (not defined) associated with mortality aOR 11.7<br>(1.4, 96.1)  |
| Meyer<br>2005   | Risk score for pediatric<br>cancer patients admitted<br>to the ICU              | Oncology patients<br>HSCT patients                                | Within 2 hours of<br>PICU admission                 | Mortality  | For a risk score cutoff value of >3 points:<br>Se: 100% (CI: 65, 100)<br>Sp: 92% (CI: 74, 99)<br>PPV: 100% (CI: 86, 100)<br>NPV: 78% (CI: 40, 97)<br>Factors included in the risk score: non-solid tumor, > 2 organ failures,<br>neutropenia, septic shock, mechanical ventilation, and inotropic medication   |
| Peters<br>2001  | Blood cell counts   | Clinical<br>meningococcal<br>disease                              | first obtained<br>values                            | Mortality  | Se: 73% for platelets x ANC product < 40<br>Sp: 99% for platelets x ANC product < 40<br>PPV: 82% for platelets x ANC product < 40<br>AUROC: 0.97   |
| Silva<br>2007   | Blood cell counts   | PICU patients with<br>meningococcal<br>disease                    | first platelet and<br>neutrophil counts<br>obtained | death,<br>amputations of<br>limbs or digits,<br>CNS bleed                                | Se: 28.6 (8.6-58.1) with PN <= 113<br>Sp: 96.6 (88-99) with PN <= 113<br>PPV: 66.7 with PN <= 113<br>NPV: 84.8 with PN <= 113<br>AUROC: 0.85 (0.74-0.92) with PN <= 113  |
| Ramby<br>2015   | Red cell distribution width   | All patients<br>admitted to PICU                                  | First 24 hours                                      | PICU LOS ><br>48 hours; PICU<br>Mortality  | PICU LOS > 48 hours:<br>aOR for sepsis patients 0.91 (0.73, 1.13)<br>aOR for non-sepsis patients 1.17 (1.06, 1.3)<br>AUROC 0.61<br>PICU mortality:<br>aOR 1.2 (1.07, 1.35)<br>AUROC 0.65 (0.55, 0.75)<br>PIM-2 AUROC 0.75 (0.66, 0.83)<br>PIM-2 + RDW AUROC 0.78 (0.7, 0.86)<br>Optimum cut-point for mortality: >= 14.5<br>Se 69% (52, 83); Sp 54% (50, 59); PPV 10% (6, 14); NPV 96% (93, 98)<br>Using multiple cut points for mortality: < 13.4 (low risk) and > 15.7% (high<br>risk): NPV 96.7%, PPV 12.9% |
| Li<br>2019      | Red cell distribution width   | Non-cardiac<br>admitted to PICU.                                  | First 24 hours                                      | PICU mortality   | aOR 1.79 (0.984, 2.61)<br>AUROC 0.72 (0.68, 0.77)<br><br>RDW >= 15.5 (optimum cut point):<br>Se 75.8 (66.1, 83.8)<br>Sp 63.6 (57.9, 69)<br>PPV 40.4% (33.2, 47.7)<br>NPV 89% (84.1, 92.8)  |
| Said<br>2017    | Red cell distribution width   | General PICU<br>population (mixed<br>cardiac and non-<br>cardiac) | First CBC in first 24<br>hours                      | PICU mortality<br>or ECMO  | AUROC 0.611<br>AUROC for PIM-2: 0.901<br>AUROC for combined PIM-2 and RDW: 0.904<br>aOR, controlling for PIM-2, 1.127  |



|                   |  |   |                          |                    |   |
|-------------------|--|---|--------------------------|--------------------|---|
| Kim 2019          | Hematocrit; pSOFA, PELOD                                 | Oncology patients                                 | Day 1                    | Mortality          | Hematocrit: aOR 0.86 (0.76, 0.96)<br>pSOFA: AUROC (95%CI) 0.8 (0.72, 0.88)<br>PELOD: AUROC (95% CI) 0.76 (0.67, 0.84)   |
| Nam 2018          | Combined delta neutrophil index and mean platelet volume | Other<br>Unable to determine PICU characteristics | Not reported             | Mortality, Sepsis  | Sepsis: delta neutrophil% AUC 0.97; neutrophil distribution width AUC 0.79; monocyte distribution width AUC 0.77; platelet count AUC 0.79; mean platelet volume AUC 0.66; plateletcrit AUC 0.79; immature platelet fraction AUC 0.77<br>Mortality: WBC count HR 9.12 (2.8,29.6); delta neutrophil% HR 19 (2.4, 151); neutrophil distribution width HR 15 (3.3, 70); monocyte distribution width HR 1.3 (1.2, 1.5); platelet count HR 1.56 (0.46, 5.24); mean platelet volume HR 14 (1.7, 113); immature platelet fraction HR 12 (1.5, 97); delta neutrophil% plus mean platelet volume AUC 0.99   |
| Niederwanger 2018 | Blood Cell Counts  | Sepsis  | Day of peak level of CRP | Mortality          | Platelet count: aOR for survival: 1.94 (1.3, 3.3) per 50,000  |
| Ye 2018           | Platelet volume indices and red cell distribution width  | Children on mechanical ventilation                | Not reported             | PICU mortality     | For children > 3 years of age:<br>Univariate analysis: Platelet count 292 +/- 102 (survivors) vs 193 +/- 129 (NS) p < 0.001<br>Platelet count: aOR 1.01 (1, 1.01) on multivariable analysis<br>Longitudinal MPV over the first week of ICU admission, non-survivors appear to have decrease in MPV over the first 72 hours followed by increase<br>Univariate analyses: PDW 58 +/- 23 (survivors) vs. 48 +/- 25 (nonsurvivors), p 0.01 (not significant on multivariable analysis); RDW 13.2 +/- 1.7 (survivors) vs 14.1 +/- 2.2 (nonsurvivors) p<0.001 (multivariable analysis nonsignificant)<br>For infants and children < 3 years of age:<br>Univariate analysis: Platelets count 340.6 +/- 147 (survivors) vs 319.6 +/- 168 (NS) p<0.001; No significant difference in PDW between survivors and nonsurvivors; RDW 14.5 +/- 2.5 (survivors) vs 13.9 +/- 2 (NS) p < 0.001 |
| Jain 2018         | Blood cell counts  | Severe community acquired pneumonia               | Hospital admission       | mortality          | Platelet count < 70,000 aOR 10.7 (1.3, 78.7)  |
| Kalkwarf 2018     | Blood cell counts  | Severe trauma                                     | Admission                | mortality          | Platelet count:<br>< 30,000 100% PPV; 92% NPV, Se 1%, Sp 100%<br>< 40,000 67% PPV, 92% NPV, Se 2%, Sp 99%<br>< 50,000 60% PPV, 92%NPV, Se 3%, Sp 99%<br>< 60,000 33% PPV, 92% NPV, Se 3%, Sp 99%<br>< 70,000 40%PPV, 92%NPV, Se 4%, Sp 99%<br>Hb < 5: 100% PPV, 92% NPV   |
| Sachdev 2018      | Red cell distribution width                              | PICU patients                                     | Admission                | Hospital mortality | Day 1 RDW:<br>15.7 – 18.04, aOR 1.05 (0.95, 1.16)<br>18.04 – 21.5 aOR 1.26 (1, 1.59)<br>≤ 21.5 aOR 1.4 (1.06, 1.83)   |

Abbreviations: aOR, adjusted odds ratio; AUROC, area under the receiver operating characteristics curve; HR, Hazard Ratio; KM, Kaplan Meier curve; LR, Likelihood Ratio; MV, multivariable; PPV, positive predictive value; NPV, negative predictive value; Se - sensitivity; Sp, specificity; NICU, neonatal intensive care unit; PICU, pediatric intensive care unit; BiPAP, Bilevel positive airway pressure; BNP, brain natriuretic peptide; CDH, congenital diaphragmatic hernia; CHD, congenital heart disease; CK, creatine kinase; CO, cardiac output; CPAP, continuous positive airway pressure; CPR, cardiopulmonary resuscitation; CRP, C-reactive protein; CRT, capillary refill time; DCM, dilated cardiomyopathy; ECG, electrocardiogram; Echo, Echocardiogram; ECMO, extracorporeal membrane oxygenation; EF, ejection fraction; HIE, Hypoxic ischemic encephalopathy; ISS, severity of injury score; LR, likelihood ratio; LV, left ventricle; LSI, life-saving intervention; MCS, mechanical circulatory support; mins, minutes; mo, months; MPI, myocardial performance index (Tei Index); NIRS, near infrared spectroscopy; NYHA, New York Heart Association; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; PCICU, pediatric cardiac intensive care unit; PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality score; RV, right ventricle; SD/DD - systole to diastole duration; Se, sensitivity; SI, shock index; SIPA, age adjusted shock index; Sp, specificity; yr, years

## References<sup>1-29</sup>

1. An K, Wang Y, Li B, et al. Prognostic factors and outcome of patients undergoing hematopoietic stem cell transplantation who are admitted to pediatric intensive care unit. *BMC Pediatr*. 2016;16(1):138.
2. Bestati N, Leteurtre S, Duhamel A, et al. Differences in organ dysfunctions between neonates and older children: a prospective, observational, multicenter study. *Crit Care*. 2010;14(6):R202.
3. Castellanos-Ortega A, Delgado-Rodriguez M, Llorca J, et al. A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems. *Intensive Care Med*. 2002;28(3):341-351.
4. Chhangani NP, Amandeep M, Choudhary S, Gupta V, Goyal V. Role of acute physiology and chronic health evaluation II scoring system in determining the severity and prognosis of critically ill patients in pediatric intensive care unit. *Indian J Crit Care Med*. 2015;19(8):462-465.
5. Choi S, Ha E, Jhang WK, Park SJ. Platelet Indices as Predictive Markers of Prognosis in Pediatric Septic Shock Patients. *Iran J Pediatr*. 2017;27(3).
6. Couto-Alves A, Wright VJ, Perumal K, et al. A new scoring system derived from base excess and platelet count at presentation predicts mortality in paediatric meningococcal sepsis. *Crit Care*. 2013;17(2):R68.
7. da Silva ED, Koch Nogueira PC, Russo Zamataro TM, de Carvalho WB, Petrilli AS. Risk factors for death in children and adolescents with cancer and sepsis/septic shock. *J Pediatr Hematol Oncol*. 2008;30(7):513-518.
8. Fijnvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. *Thromb Haemost*. 1995;73(1):15-20.
9. Gonzalez-Vicent M, Marin C, Madero L, Sevilla J, Diaz MA. Risk score for pediatric intensive care unit admission in children undergoing hematopoietic stem cell transplantation and analysis of predictive factors for survival. *J Pediatr Hematol Oncol*. 2005;27(10):526-531.
10. Hu G, Lang H, Guo H, et al. A risk score based on admission characteristics to predict progressive hemorrhagic injury from traumatic brain injury in children. *Eur J Pediatr*. 2017;176(6):689-696.
11. Jain A, Awasthi N, Awasthi S. Low platelet counts predict mortality in severe community acquired pneumonia in children under 5 years of age: A hospital based observational study. *Clin Epidemiol Glob*. 2018;6(4):188-191.
12. Jhang WK, Ha EJ, Park SJ. Evaluation of Disseminated Intravascular Coagulation Scores in Critically Ill Pediatric Patients. *Pediatr Crit Care Med*. 2016;17(5):e239-246.
13. Kalkwarf KJ, Jensen SD, Allukian M, 3rd, et al. Can We Identify Futility in Kids? An Evaluation of Admission Parameters Predicting 100% Mortality in 1,292 Severely Injured Children. *J Am Coll Surg*. 2018;226(4):662-667.
14. Kim K, Kim S, Lee JW, Yoon JS, Chung NG, Cho B. Prognostic Factors of ICU Mortality in Pediatric Oncology Patients With Pulmonary Complications. *J Pediatr Hematol Oncol*. 2020;42(4):266-270.
15. Kornelisse RF, Hazelzet JA, Hop WC, et al. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. *Clin Infect Dis*. 1997;25(3):640-646.
16. Leteurtre S, Duhamel A, Salleron J, et al. PELOD-2: an update of the PEdiatric logistic organ dysfunction score. *Crit Care Med*. 2013;41(7):1761-1773.

17. Li G, Jia P, Zhao J, et al. Usefulness of RBC distribution width and C-reactive protein to predict mortality in pediatric non-cardiac critical illness. *Am J Emerg Med*. 2019;37(12):2143-2150.
18. Malley R, Huskins WC, Kuppermann N. Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. *J Pediatr*. 1996;129(5):702-710.
19. Martins L, Macao P, Pinto C, et al. Invasive Meningococcal Disease: Application of Base Excess and Platelets Score in a Portuguese Paediatric Intensive Care Unit. *Acta Med Port*. 2015;28(3):342-346.
20. Meyer S, Gottschling S, Biran T, et al. Assessing the risk of mortality in paediatric cancer patients admitted to the paediatric intensive care unit: a novel risk score? *Eur J Pediatr*. 2005;164(9):563-567.
21. Nam M, Son BH, Seo JE, Kim IR, Park CK, Kim HK. Improved Diagnostic and Prognostic Power of Combined Delta Neutrophil Index and Mean Platelet Volume in Pediatric Sepsis. *Ann Clin Lab Sci*. 2018;48(2):223-230.
22. Niederwanger C, Bachler M, Hell T, et al. Inflammatory and coagulatory parameters linked to survival in critically ill children with sepsis. *Ann Intensive Care*. 2018;8(1):111.
23. Peters MJ, Ross-Russell RI, White D, et al. Early severe neutropenia and thrombocytopenia identifies the highest risk cases of severe meningococcal disease. *Pediatr Crit Care Med*. 2001;2(3):225-231.
24. Purbiya P, Golwala ZM, Manchanda A, Sreenivas V, Puliyl JM. Platelet Distribution Width to Platelet Count Ratio as an Index of Severity of Illness. *Indian J Pediatr*. 2018;85(1):10-14.
25. Ramby AL, Goodman DM, Wald EL, Weiss SL. Red Blood Cell Distribution Width as a Pragmatic Marker for Outcome in Pediatric Critical Illness. *PLoS One*. 2015;10(6):e0129258.
26. Sachdev A, Simalti A, Kumar A, Gupta N, Gupta D, Chugh P. Outcome Prediction Value of Red Cell Distribution Width in Critically-ill Children. *Indian Pediatr*. 2018;55(5):414-416.
27. Said AS, Spinella PC, Hartman ME, et al. RBC Distribution Width: Biomarker for Red Cell Dysfunction and Critical Illness Outcome? *Pediatr Crit Care Med*. 2017;18(2):134-142.
28. Silva PS, Iglesias SB, Nakakura CH, de Aguiar VE, de Carvalho WB. The product of platelet and neutrophil counts (PN product) at presentation as a predictor of outcome in children with meningococcal disease. *Ann Trop Paediatr*. 2007;27(1):25-30.
29. Ye S, Zhang Y, Zhang C, Xu D. Are platelet volume indices related to mortality in hospitalized children on mechanical ventilation? *J Int Med Res*. 2018;46(3):1197-1208.

## **Research Priorities**

1. What thresholds of cytopenia are most predictive of adverse outcomes in critically ill children?
2. Should the definition of hematologic dysfunction include the cause(s) of cytopenias, with “marrow failure” defined as cytopenias resulting from decreases in cellular production compared to normal values and “insufficient compensatory production” defined as cytopenias resulting from increased destruction or utilization of a cell type?
3. Should the definition of hematologic dysfunction include abnormal function in addition to abnormal quantity of cells/cellular components?